PRO Uncut

Uncut: Full interview with Juno Therapeutics CEO

Hans Bishop, CEO of Juno Therapeutics, gave a revealing update on the company in an exclusive interview with CNBC's Meg Tirrell at the ASH conference.

Juno is up 40 percent since it went public in December of last year, but the shares fell 7 percent Monday.

Bishop commented on Juno Therapeutics' latest data, competitor study releases and the long-term strategy of the company.

Can't see the video? Here's how to become a CNBC Pro subscriber.